Off-label use of ceftaroline fosamil: A systematic review

Pani, Arianna; Colombo, Fabrizio; Agnelli, F.; Frantellizzi, Viviana; Baratta, Francesco; Pastori, Daniele; Scaglione, Francesco

doi:10.1016/j.ijantimicag.2019.06.025

Cited by 32 publications

(27 citation statements)

References 38 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, daptomycin is of no use in treating lung infections as it binds surfactant with its consequent inactivation [52]. Interestingly, ceftaroline, which is often overlooked, has a good efficacy on MRSA, maintaining the safety of a cephalosporin with a variety of indications both on or off label [53], and has been approved for children older than two months of age without a recognized widespread resistance so far identified.…”

Section: Resistant Staphylococcus Aureusmentioning

confidence: 99%

Antibiotic Resistance in Pediatric Infections: Global Emerging Threats, Predicting the Near Future

et al. 2021

Self Cite

View full text Add to dashboard Cite

Antibiotic resistance is a public health threat of the utmost importance, especially when it comes to children: according to WHO data, infections caused by multidrug resistant bacteria produce 700,000 deaths across all ages, of which around 200,000 are newborns. This surging issue has multipronged roots that are specific to the pediatric age. For instance, the problematic overuse and misuse of antibiotics (for wrong diagnoses and indications, or at wrong dosage) is also fueled by the lack of pediatric-specific data and trials. The ever-evolving nature of this age group also poses another issue: the partly age-dependent changes of a developing system of cytochromes determine a rather diverse population in terms of biochemical characteristics and pharmacokinetics profiles, hard to easily codify in an age- or weight-dependent dosage. The pediatric population is also penalized by the contraindications of tetracyclines and fluoroquinolones, and by congenital malformations which often require repeated hospitalizations and pharmacological and surgical treatments from a very young age. Emerging threats for the pediatric age are MRSA, VRSA, ESBL-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae and the alarming colistin resistance. Urgent actions need to be taken in order to step back from a now likely post-antibiotic era, where simple infections might cause infant death once again.

show abstract

Section: Resistant Staphylococcus Aureusmentioning

confidence: 99%

Antibiotic Resistance in Pediatric Infections: Global Emerging Threats, Predicting the Near Future

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although most of these antibiotics are not approved for these indications, they might also be used to treat IE, osteomyelitis, and osteosynthesis-associated infections. Previous reviews have been published on the use of just a few of these novel antibiotics in complicated infections [5,6]. Other reviews focused on the use of these novel antibiotics for approved indications [7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis

Bloem

Bax

Yusuf

et al. 2021

JCM

View full text Add to dashboard Cite

Infective endocarditis, osteomyelitis, and osteosynthesis-associated infections are mostly caused by Gram-positive bacteria. They are often difficult to treat and are associated with a poor prognosis. In the past 20 years, nine antibiotic drugs with predominant activity against Gram-positive bacteria have been introduced and approved by the Food and Drug Administration or the European Medicines Agency: ceftaroline, daptomycin, telavancin, dalbavancin, oritavancin, linezolid, tedizolid, delafloxacin, and omadacycline. This narrative review aims to provide an overview on these antibiotics with a special focus on their use in infective endocarditis, osteomyelitis, and osteosynthesis-associated infections. Although some of these approved antibiotics are promising, they should not be used as first- or second-line therapy, awaiting more clinical data.

show abstract

“…Moreover, most trials focus on disease state rather than pathogen resistance patterns. Once approved, these antibiotics are often used offlabel for more serious infections [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Clinical Outcomes of Patient Subgroups in the TANGO II Study

Bhowmick

2021

Infect Dis Ther

View full text Add to dashboard Cite

Introduction: Meropenem-vaborbactam (M-V), a new approved antimicrobial, was developed specifically to be effective treatment for the increasingly prevalent and difficult to treat carbapenem-resistant Enterobacterales (CRE) infections. However, registration phase 3 clinical studies offer limited applicability to daily medical practice as they often focus on indications such as urinary tract infections or skin and soft tissue infections, which generally have patients with fewer comorbid conditions that the typical patients who develops infection with CRE. The more useful studies are pathogen-focused trials which do not exclude the more complicated subjects with conditions such as renal failure, immunocompromised status, or exposure to prior antibiotic therapy. Methods: The TANGO II study was an open-label investigation of M-V compared with the best available treatment (BAT) in hospitalized adults with a confirmed infection that was known or suspected to be a CRE infection. TANGO II specifically included patients with comorbidities, prior antibiotic therapy, renal failure, and immunocompromised status that are typical in patients with a CRE infection. Interim data analysis indicated that a significant benefit was seen for those patients receiving M-V over BAT. This analysis reports on subsets of TANGO II study patients with multiple comorbidities and high severity of illness, specifically those with prior antibiotic therapy, renal failure, and immunocompromised status. A patient case that highlights particular complexities and challenges of treating patients with CRE infections in the real world is also presented. Results: Subjects with comorbid conditions had better outcomes when given M-V rather than BAT. Conclusion: M-V is a welcome addition to the antibiotic armamentarium for the treatment of severe CRE infections in complicated patients. Trial Registration: ClinicalTrials.gov identifier NCT02168946.

show abstract

Off-label use of ceftaroline fosamil: A systematic review

Cited by 32 publications

References 38 publications

Antibiotic Resistance in Pediatric Infections: Global Emerging Threats, Predicting the Near Future

Antibiotic Resistance in Pediatric Infections: Global Emerging Threats, Predicting the Near Future

New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis

Clinical Outcomes of Patient Subgroups in the TANGO II Study

Contact Info

Product

Resources

About